1 – 50 of 179
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
2024) In The Lancet Haematology(
- Contribution to journal › Article
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
2024) In Haemophilia(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Real-world prophylactic usage of recombinant factor IX Fc in Sweden : A report from the Swedish National Registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
Koagulationsfaktor XIII – inte bara ett kongenitalt blödningsproblem
(
- Contribution to journal › Scientific review
-
Mark
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
(
- Contribution to journal › Article
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
(
- Contribution to journal › Scientific review
-
Mark
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
(
- Contribution to journal › Article
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
(
- Contribution to journal › Article
-
Mark
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B : post hoc analysis of phase III trials using patient-reported outcomes
(
- Contribution to journal › Article
-
Mark
High use of pain, depression, and anxiety drugs in hemophilia : more than 3000 people with hemophilia in an 11-year Nordic registry study
(
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
- 2022
-
Mark
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B : Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
(
- Contribution to journal › Article
-
Mark
New Inhibitors in the Ageing Population : A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia
(
- Contribution to journal › Article
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
-
Mark
International consensus recommendations on the management of people with haemophilia B
(
- Contribution to journal › Scientific review
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
-
Mark
Autologous cell therapy - A new concept to eradicate inhibitors in haemophilia
(
- Contribution to journal › Letter
-
Mark
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
(
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children : A critical review from the physician's perspective
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
(
- Contribution to journal › Article
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Identification of F8 rearrangements in carrier and non-carrier mothers of haemophilia A patients
(
- Contribution to journal › Letter
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
-
Mark
Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors : A systematic literature review
(
- Contribution to journal › Scientific review
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
(
- Contribution to journal › Article
-
Mark
Efficacy of rfixfc versus rix-fp for the treatment of patients with hemophilia b : Matching-adjusted indirect comparison of b-long and prolong-9fp trials
(
- Contribution to journal › Article
-
Mark
Droplet digital PCR and mile-post analysis for the detection of F8 int1h inversions
(
- Contribution to journal › Article
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
- 2020
-
Mark
Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR
(
- Contribution to journal › Article
-
Mark
Detection of F8 int22h inversions using digital droplet PCR and mile-post assays
(
- Contribution to journal › Article
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
(
- Contribution to journal › Article
- 2019
-
Mark
Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia : A comparison between intermediate- and high-dose prophylaxis
(
- Contribution to journal › Article
-
Mark
Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study
(
- Contribution to journal › Article
-
Mark
Joint comorbidities among Swedish carriers of haemophilia : A register-based cohort study over 22 years
(
- Contribution to journal › Article
-
Mark
Targeted re-sequencing of F8, F9 and VWF : Characterization of Ion Torrent data and clinical implications for mutation screening
(
- Contribution to journal › Article
- 2018
-
Mark
The role of the laboratory in diagnosis and management of inhibitory antibodies in haemophilia
(
- Contribution to journal › Article
- 2017
-
Mark
The importance of genetic factors for the development of arthropathy : A longitudinal study of children and adolescents with haemophilia A
(
- Contribution to journal › Article
-
Mark
Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics
(
- Contribution to journal › Article